1.74 Indication means the intended use of a Licensed Product for either therapeutic treatment or for the prevention of a distinct illness, sickness, interruption, cessation or disorder of a particular bodily function, system, tissue type or organ, or sign or symptom of any such items or conditions, regardless of the severity, frequency or route of any treatment, treatment regimen, dosage strength or patient class, for which any Marketing Approval is being sought and which will be referenced on any Licensed Product labelling in any country. [***].
1.75 Infringement as defined in Section 11.4.1.
1.76 Intellectual Property means Patents and Know-How.
1.77 Investor Information as defined in Section 13.3.1.
1.78 Investor Presentation(s) as defined in Section 13.3.1.
1.79 IPR as defined in Section 11.1.3.
1.80 IPWG as defined in Section 2.1.4.
1.81 JDC as defined in Section 2.1.1.
1.82 JPT as defined in Section 2.1.4.
1.83 JRC as defined in Section 2.1.1.
1.84 Know-How means all information, inventions (whether or not patentable), improvements, practices, formula, trade secrets, techniques, methods, procedures, knowledge, results, test data (including pharmacological, toxicological, pharmacokinetic and pre-clinical and clinical information and test data, related reports, structure-activity relationship data and statistical analysis), analytical and quality control data, protocols, processes, models, designs, TCR sequence information, and other information regarding discovery, Development, marketing, pricing, distribution, cost, sales and manufacturing. Know-How shall not include any Patents.
1.85 Licensed Product means: (a) a Shared Antigen TCR Product or a Private Antigen TCR Product, individually or collectively as the context may require; and (b) following [***], any biopharmaceutical composition(s), preparation(s) or formulation(s) that contains any Shared Antigen TCR or Private Antigen TCR expressed in the applicable Shared Antigen TCR Product or Private Antigen TCR Product for which such First Commercial Sale in an oncology Indication occurred.
1.86 Loss or Losses as defined in Section 15.1.
1.87 Major European Market means France, Germany, Spain, Italy or the United Kingdom.
1.88 Marketing Approval means all approvals, licenses, registrations or authorizations of any federal, state or local regulatory agency, department, bureau or other governmental entity, necessary for the manufacturing, use, storage, import, transport and sale of Licensed Products in a country or regulatory jurisdiction. For countries where governmental approval is required for pricing or reimbursement for the Licensed Product, Marketing Approval shall not be deemed to occur until such pricing or reimbursement approval is obtained.
Certain information, as identified by [***], has been excluded from this agreement because it (i) is not material and (ii) would be competitively harmful if publicly disclosed.